References
- Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, et al.; Cancer Vaccine Clinical Trial Working Group. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007; 30:1-15; PMID:17198079; http://dx.doi.org/10.1097/01.cji.0000211341.88835.ae
- Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102:1388-97; PMID:20826737; http://dx.doi.org/10.1093/jnci/djq310
- Di Lorenzo G, Buonerba C. Kidney cancer: Overall Survival is an unsuitable primary clinical endpoint. Nature Urology 2010; 7:367-8; http://dx.doi.org/10.1038/nrurol.2010.84
- Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624
- Gomella L, Nabhan C, DeVries T, Whitmore J, Frohlich M. Estimating the overall survival benefit of sipuleucel-T in the IMPACT trial accounting for crossover treatment in control subjects with autologous immunotherapy generated from cryopreserved cell. J Urol 2012; 187:E278-9; http://dx.doi.org/10.1016/j.juro.2012.02.765
- Schmidt C. Ovarian cancer treatments on the horizon. J Natl Cancer Inst 2011; 103:1284-5; PMID:21852261; http://dx.doi.org/10.1093/jnci/djr343
- Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol 2012; 61:639-47; PMID:22036643; http://dx.doi.org/10.1016/j.eururo.2011.10.027
- Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12:237-51; PMID:22437869; http://dx.doi.org/10.1038/nrc3237
- Chabner BA. Early accelerated approval for highly targeted cancer drugs. N Engl J Med 2011; 364:1087-9; PMID:21428763; http://dx.doi.org/10.1056/NEJMp1100548
- Coutant D, Riggs D, Hoffman EV. Substantial Evidence: When Is a Single Trial Sufficient for Approval and Promotion? Drug Inf J 2011; 45:253-63
- Witten C. FDA and Cancer Vaccine Development. 2008; Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/newsevents/workshopsmeetingsconferences/ucm102978.pdf Accessed on November 11th, 2013.